4 results match your criteria: "The State University of Amazon[Affiliation]"
A Second Wind for Inorganic APIs: Leishmanicidal and Antileukemic Activity of Hydrated Bismuth Oxide Nanoparticles.
Pharmaceutics
June 2024
Post-Graduate Program in Hematology, The State University of Amazon, Foundation of Hematology and Hemotherapy of Amazonas, Manaus 69050-010, AM, Brazil.
American cutaneous leishmaniasis is a disease caused by protozoa of the genus Leishmania. Currently, meglumine antimoniate is the first-choice treatment for the disease. The limited efficacy and high toxicity of the drug results in the necessity to search for new active principles.
View Article and Find Full Text PDFImmunomodulatory and Anticancer Effects of Extract-Loaded Nanocapsules in Myeloid Leukemia.
Pharmaceutics
June 2024
Post-Graduate Program in Hematology, The State University of Amazon (UEA), Foundation of Hematology and Hemotherapy of Amazonas, Manaus 69050-010, AM, Brazil.
Nanocapsules provide selective delivery and increase the bioavailability of bioactive compounds. In this study, we examined the anticancer and immunomodulatory potential of (crajiru) extract encapsulated in nanocapsules targeting myeloid leukemias. Nanocapsules containing crajiru (nanocapsules-CRJ) were prepared via interfacial polymer deposition and solvent displacement.
View Article and Find Full Text PDFPharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7',8'-Dimethoxy-1',3'-dimethyl-1,2,3',4'-tetrahydrospiro[indole-3,5'-pyrazolo[3,4-c]isoquinolin]-2-one) in chronic myeloid leukemia.
Invest New Drugs
October 2023
Post-Graduate Program in Basic and Applied Immunology, Institute of Biological Science, Federal University of Amazonas, Manaus, 69077-000, AM, Brazil.
Article Synopsis
- This study focused on a newly developed spiroindolone derivative and its potential as a cancer treatment, specifically for chronic leukemia.
- The compound was tested on cancerous K562 cells and showed significant cytotoxic effects while causing minimal harm to normal cells.
- Results indicated that the compound not only halted cancer cell growth by inducing G2/M cell cycle arrest but also boosted the production of important immune cytokines, suggesting its dual role as an anti-cancer and immunomodulatory agent.
Cytotoxic and immunomodulatory potential of a novel [2-(4-(2,5-dimethyl-1H-pyrrol-1-yl)-1H-pyrazol-3-yl)pyridine] in myeloid leukemia.
Biomed Pharmacother
June 2023
Post-Graduate Program in Basic and Applied Immunology, Institute of Biological Science, Federal University of Amazonas, Manaus 69077-000, AM, Brazil; Laboratory of Virology and Immunology, National Institute of Amazonian Research (INPA), Manaus 69067-375, AM, Brazil; Post-Graduate Program in Hematology, The State University of Amazon, Foundation of Hematology and Hemotherapy of Amazonas, Manaus 69050-010, AM, Brazil. Electronic address:
Cancer ranks among the leading causes of mortality worldwide. However, the efficacy of commercially available anticancer drugs is compromised by the emerging challenge of drug resistance. This study aimed to investigate the anticancer and immunomodulatory potential of a recently developed a novel [2-(4-(2,5-dimethyl-1 H-pyrrol-1-yl)- 1 H-pyrazol-3-yl) pyridine].
View Article and Find Full Text PDF